Page 2 - Lawrencef Eichenfield News Today

Deciding on treatment, treatment side effects, self-image issues, topical regimen adherence, and quantification of disease were among the topics addressed by experts.

Longer-term safety data on two JAK inhibitors approved for treating atopic dermatitis in adolescents are accumulating.

Diagnosis requires careful consideration of mimicking conditions and a broader list of differential diagnoses in those infants with poor growth or frequent infections, Dr. Elaine Siegfried said.

The fixed-combination IDP-126 showed promising results as the first triple-combination product for the treatment of acne in patients aged as young as 9 years, according to a study.“Efficacy, tolerability and adherence to treatment with topical therapies may be improved by delivering them in fixed-combination formulations utilizing enhanced vehicles,” Lawrence F. Eichenfield, MD, chief

A recent analysis showed that a combination treatment made of phosphate, adapalene, and benzoyl peroxide known as IDP-126 was well-tolerated and effective in pediatric participants with acne.

NEW ORLEANS — Patients with atopic dermatitis experienced a rapid and sustained reduction in itch with topical roflumilast cream treatment, according to phase 3 study results presented at the American Academy of Dermatology Annual Meeting.“The study supports that roflumilast cream 0.15% showed efficacy, good safety and very good tolerance for children and adults with atopic dermatitis

Emerging research suggests that there may be a role for oral omega-3 in reducing these side effects, which include cheilitis and dry skin.

Ruxolitinib cream provides quick itch relief for Black patients with atopic dermatitis, researchers report.

/PRNewswire/ -- Following the success of last years conference, Medscape Education will host the second annual spring edition of the Innovations in...

These findings highlight the importance of detailed assessment of specific areas affected by AD to personalize treatment approaches to the needs of patients, Dr Lawrence Eichenfield said.